Literature DB >> 18242155

Effect of the 5-HT3 receptor antagonist, ondansetron, on gastric size in dyspeptic patients with impaired gastric accommodation.

L Marzio1, G Cappello, L Grossi, L Manzoli.   

Abstract

BACKGROUND: A reduction of gastric accommodation after a meal has been documented in patients with idiopathic dyspepsia. In these patients the administration of a 5-HT3 receptor antagonist may reduce some of the dyspeptic symptoms; it is not clear however, whether these drugs influence gastric adaptation to distension as well. AIM: To evaluate the effects of the 5-HT3 receptor antagonist, ondansetron, on gastric distension after a liquid meal in dyspeptic patients with reduced gastric accommodation.
METHODS: Before and after a 500 ml water load, gastric accommodation (area of the proximal and distal stomach) was evaluated using real-time ultrasonography in 21 idiopathic dyspepsia patients and 26 healthy controls. In dyspeptic patients, the test was repeated twice: after the administration of placebo and after ondansetron 8 mg i.v. (in both cases, 15 min prior to the water load). Secondary outcomes were epigastric pain, fullness and nausea as assessed by a visual analogue scale at basal and after ondansetron.
RESULTS: Fasting gastric size was similar in dyspeptic and controls. Compared with controls, dyspeptic patients showed a statistically significant smaller area of the proximal stomach (14.7+/-1.2 cm(2) vs. 18.6+/-1.4 cm(2), respectively; p=0.0247). In dyspeptic patients, gastric proximal and distal size did not change significantly following placebo, whereas after the administration of ondansetron the mean area of the proximal and distal stomach significantly increased (proximal stomach: 14.6+/-1.6 cm(2) placebo, 20.4+/-1.9 cm(2) ondansetron, p=0.0095; distal stomach: 8.9+/-0.9 placebo, 11.4+/-1.2cm(2) ondansetron, p=0.0409). Of the symptoms, only nausea was significantly reduced after ondansetron.
CONCLUSION: In dyspeptic patients with impaired gastric accommodation, ondansetron reverts gastric accommodation to within the range of controls.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242155     DOI: 10.1016/j.dld.2007.11.013

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

Review 1.  Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.

Authors:  John M Rosen; Jose T Cocjin; Jennifer V Schurman; Jennifer M Colombo; Craig A Friesen
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

2.  Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children.

Authors:  Leonel Rodriguez; Juan Diaz; Samuel Nurko
Journal:  J Pediatr       Date:  2013-02-16       Impact factor: 4.406

3.  From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2017-06-02       Impact factor: 3.199

4.  Measurement of Gastric Residual Volume via Ultrasound after Receiving Intravenous Ondansetron, Metoclopramide, and Neostigmine in Critically Ill Patients: A Double-Blind Clinical Trial.

Authors:  Behrooz Farzanegan; Navid Shafigh; Jalal Heshmatnia; Seyed Mohammadreza Hashemian; Mehran Malekshoar; Golnaz Afzal; Hamidreza Jamaati; Mehdi Kazempour-Dizaji; Mohammad Fathi
Journal:  Tanaffos       Date:  2021-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.